Joseph L. Goldstein
Known title: DirectorCIK: 0001225474
Associated companies
Transaction History
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,707 | $1.7M | 1/23/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 2,707 | $2.6M | 1/23/2024 | View on chart |
| REGN | ▲ Buy | Grant | 135 | $0 | 1/2/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 3,613 | $2.9M | 2/6/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,613 | $1.7M | 2/6/2023 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,431 | $909K | 3/30/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 2,431 | $1.7M | 3/30/2022 | View on chart |
| REGN | ▲ Buy | Grant | 191 | $0 | 1/3/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,479 | $944K | 9/10/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 2,479 | $1.6M | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.